Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anthony Sin

Neurological Surgery Shreveport, LA Medical Doctor

NPI 1073738613 CMS profile 479642

1501 Kings Hwy, Shreveport, LA 71103

Open in the dashboard

General payments

$1,541,636

107 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$448,987

7 holdings reported · through program year 2025

Through program year 2025, Anthony Sin of Shreveport, LA is reported in the CMS Open Payments database as having received $1,541,636 across 107 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $448,987 across 7 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $763,649 15
2024 General $518,391 6
2023 General $61,275 5
2022 General $120,811 26
2021 General $49,373 17
2020 General $13,483 15
2019 General $14,655 23
2025 Ownership $64,141 1
2024 Ownership $64,141 1
2023 Ownership $64,141 1
2022 Ownership $64,141 1
2021 Ownership $64,141 1
2020 Ownership $64,141 1
2019 Ownership $64,141 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anthony Sin
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Anthony Sin were reported at $763,649. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Anthony Sin Neurological Surgery median Middle half National median
2019 $14,655 $582 $138–$3,006 $163
2020 $13,483 $294 $76–$2,174 $114
2021 $49,373 $387 $105–$2,432 $132
2022 $120,811 $542 $139–$2,989 $149
2023 $61,275 $534 $145–$2,697 $160
2024 $518,391 $574 $155–$3,046 $164
2025 $763,649 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. L&K Biomed Co. , Ltd. $711,000 2 payments
  2. Medyssey USA, Inc $696,877 7 payments
  3. GS Solutions, Inc. $98,518 6 payments
  4. Aegis Spine, Inc. $27,032 3 payments
  5. Medtronic USA, Inc. $2,565 21 payments
  6. Sanara MedTech Inc. $1,439 17 payments
  7. Medtronic, Inc. $1,359 17 payments
  8. Globus Medical, Inc. $1,304 4 payments
  9. Stryker Corporation $377 5 payments
  10. DePuy Synthes Sales Inc. $287 6 payments
  11. Other $878 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $1,509,800 10 payments
  2. Royalty or License $21,032 2 payments
  3. Food and Beverage $8,242 90 payments
  4. Travel and Lodging $2,563 5 payments
Products named General payments · program years 2019–2025
  1. AccelFix-XT $11,991 1 payment
  2. AccelFix Lumbar Expandable Cage System $9,041 1 payment
  3. CD HORIZON $2,346 11 payments
  4. CellerateRx $1,439 17 payments
  5. Excelsius Robotics System $703 2 payments
  6. MAZOR X SYSTEM $620 8 payments
  7. Spine $486 1 payment
  8. Mazor X Stealth Edition $298 3 payments
  9. UNID_PASS $213 2 payments
  10. Kerecis SurgiClose $204 2 payments
  11. Other $2,682 55 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

144

Median for Neurosurgery: 83

Drug cost

$828

Median for Neurosurgery: $872

Branded share of claims

0%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 26 $259
Methylprednisolone Generic 29 $197
Meloxicam Generic 47 $165
Gabapentin Generic 19 $108
Methocarbamol Generic 11 $65
Tramadol Hcl Generic 12 $34

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$261,409

Medicare's payments for the services billed

Medicare patients

291

Average age 71

Services billed

876

164 women, 127 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 37%
Diabetes 36%
Depression 31%
COPD 23%
Osteoporosis 22%
Chronic kidney disease 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

107 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record